What changed for Long COVID
A plain English summary of what recently moved in the public data Voxsanity tracks for Long COVID. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 122 to 116 (-6)
- Trials on record 931 to 927 (-4)
Newly subsidised on the PBS
No PBS-reviewed medicines are tracked for Long COVID yet, so new PBS listings cannot be reported for it. This is a gap in what Voxsanity has mapped, not a statement that no medicines are subsidised — check the PBS directly.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
Trials tracked for Long COVID that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT06038617 · results posted 13 May 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 347 children in total — 176 in the "simultaneous vaccination" group and 171 in the "sequential vaccination" group. The trial was comparing two different schedules for giving vaccines to young children: one where certain vaccines were given at the same visit at the same time, and one where they were spread across separate visits. The main thing the trial was measuring was how many children developed a fever (a temperature of 38.0°C or higher) in the two days following their vaccination visits. The reported data shows...
-
NCT05092516 · results posted 30 April 2026
According to the results reported on ClinicalTrials.gov, this trial looked at whether a home-based brain stimulation technique called transcranial direct current stimulation (tDCS) — which uses a mild electrical current applied to the scalp — had any measurable effect on thinking and mental processing. Thirty-one people took part in total: 16 were assigned to receive active tDCS and 15 received a "sham" (dummy) version that mimicked the experience without delivering the real stimulation. By the end of the study, 12 people in each group had completed it. The trial measured three areas of thinki...
-
NCT05077254 · results posted 23 April 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 32 people in total — 18 in a group without a history of injection site reactions (ISR) to a previous COVID-19 vaccine, and 14 in a group with a history of such reactions. An ISR is a localised response at the spot where a needle is inserted, such as redness or swelling. The trial was looking at how a person's immune response — measured by the level of COVID-19 antibodies in the blood — changed after receiving an additional mRNA COVID-19 vaccine dose, and it also tracked various side effects in both groups. Of the 18 p...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05954286 · results posted 13 February 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 92 people with COVID-19, split evenly into two groups of 46. One group received a drug called upamostat (400 mg), and the other received a placebo (a dummy capsule with no active ingredient). All 92 participants completed the trial. The study was measuring things like how quickly symptoms eased, how long the virus remained detectable, and how soon people got back to their normal health and activities. The reported data shows that the main thing being measured — the number of days until all COVID-19 symptoms settled t...
-
NCT06057064 · results posted 15 August 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 116 participants in total — 87 received a treatment called AZD3152 and 29 received a placebo (an inactive substitute). The vast majority completed the study: 83 in the AZD3152 group and 28 in the placebo group. The trial was measuring several things: adverse events (unwanted health events that occurred during the study), and blood levels of neutralising antibodies — proteins the body can produce that may target the COVID-19 virus — at various points in time. The reported data shows that, among those who received AZD3...
-
NCT05394025 · results posted 7 August 2025
According to the results reported on ClinicalTrials.gov, this trial involved two groups of United States veterans: 235 who had tested positive for COVID-19 (the "case" group) and 244 who had not tested positive (the "comparator" group). By the end of the study, 220 participants remained in each group. The trial was measuring whether having had COVID-19 was associated with changes in veterans' ability to carry out everyday tasks — things like cooking, managing money, bathing, and dressing — over time. The reported data shows that the main thing being measured was a disability score based on 14...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05965752 · results posted 18 July 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05965752) enrolled a total of 328 people across five groups. Each group used a brain-training computer program called BrainHQ, either on its own or combined with other approaches — including a programme called PASC CoRE, or a form of mild electrical brain stimulation called tDCS (transcranial direct current stimulation, where a very low electrical current is applied to the scalp). The trial appeared to be set up as an "umbrella" study, meaning the detailed results for each specific comparison are being reported separately...
-
NCT05205460 · results posted 11 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05205460) involved 182 people in total — 91 in each of two groups. One group received home-based telerehabilitation (supervised exercise and support delivered remotely), while the other group received education and self-directed exercise. The trial ran for 12 weeks and measured changes in exercise capacity and lung function. Not everyone finished the trial: 56 of the 91 people in the telerehabilitation group completed it, and 66 of the 91 in the education and self-exercise group completed it. The reported data shows the f...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05618587 · results posted 5 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05618587) enrolled 52 people in total — 26 in the lithium group and 26 in the placebo group. Two people in the lithium group did not complete the study, while everyone in the placebo group finished. The trial was measuring changes in fatigue and "brain fog" (difficulty thinking clearly) in participants, using questionnaire-based rating scales, along with several secondary measures including overall wellbeing, quality of life, and participants' own sense of how their symptoms had changed. The reported data shows that, on t...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04728347 · results posted 30 December 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04728347) enrolled 65 people across four groups: Cohort 1a (12 people), Cohort 1b (12 people), Cohort 2 Younger Adults (25 people), and Cohort 2 Older Adults (16 people). The trial was looking at a vaccine called ARCT-021, and it was measuring two main things: reactions that participants experienced after receiving the vaccine (such as injection-site reactions, fever, fatigue, and similar symptoms), and blood antibody levels — that is, whether the body produced proteins that recognise the coronavirus after vaccination. Th...
-
NCT04889209 · results posted 11 December 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04889209) enrolled people who had already received a primary COVID-19 vaccine course and were given a booster dose from a different — or the same — vaccine brand. The main goal was to measure the level of antibodies (proteins the immune system makes in response to the vaccine) produced against several versions of the COVID-19 virus spike protein, including the original strain and variants such as Beta, Delta, and Omicron. In total, hundreds of participants were spread across 18 groups depending on which vaccine they receiv...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05096884 · results posted 3 December 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT05096884) enrolled 14 participants, all of whom received a medication called metoprolol succinate (a type of beta blocker — a drug that slows the heart rate). The trial was looking at people experiencing breathlessness on exertion and a fast heart rate as part of Post-Acute Sequelae of COVID-19 (sometimes called "Long COVID"). Of the 14 who started, 10 completed the trial and 4 did not finish. The study took measurements at the start (baseline) and again about 12 weeks later, after 8 weeks of treatment, to see whether cert...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05323994 · results posted 17 October 2024
According to the results reported on ClinicalTrials.gov, this study enrolled 104 people who had developed a depressive episode following a COVID-19 infection. One person did not complete the study, leaving 103 who finished. The study was observational — meaning researchers watched what happened in everyday clinical practice rather than randomly assigning people to different treatments — and it tracked patients taking agomelatine (an antidepressant medication) over 8 weeks. The main thing being measured was the change in depression severity using a standard rating tool called the HAMD-17 scale,...
-
NCT04914364 · results posted 19 September 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04914364) enrolled 28 adults who had tested positive for COVID-19, of whom 25 completed the study and 3 did not finish. The trial was measuring balance and mobility in this group, looking at things like how steadily people could move and walk, how well their bodies used different senses to stay balanced, and how confident they felt in their own balance during everyday activities. The reported data shows that for the main measure — the Timed Up and Go test, which tracks how long it takes a person to stand up, walk a short...
-
NCT04359680 · results posted 26 June 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04359680) enrolled 1,407 people, split into two groups: 711 received a medicine called nitazoxanide, and 696 received a placebo (a dummy pill with no active ingredient). The trial ran for six weeks and was measuring whether nitazoxanide could reduce the number of people who developed a confirmed, symptomatic COVID-19 infection or a confirmed, symptomatic respiratory viral illness during that period. The reported data shows that for the main questions the trial was designed to answer, the results were identical between the...
-
NCT05059080 · results posted 28 July 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT05059080) enrolled 72 participants, all placed in a single group with no comparison group. The trial was measuring several things in people with COVID-19 over a period of up to six months, including the percentage who experienced COVID-19 symptoms, their breathing difficulties (called dyspnea), their respiratory-related quality of life, medical visits related to COVID-19, deaths linked to COVID-19, and re-infection with the COVID-19 virus. Notably, of the 72 people who started the trial, only 5 were recorded as having comp...
-
NCT04952402 · results posted 19 May 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 43 participants across two groups: 18 people who had previously taken part in another study called ACTIV-2/A5401 (which involved experimental COVID-19 treatments), and 25 people who had never had COVID-19 before (described as "COVID-19 Naïve"). The trial was measuring how the body responds to COVID-19 vaccination by looking at levels of neutralising antibodies — these are proteins the immune system makes that can potentially block a virus. All 43 participants completed the two-dose vaccine series, though a small numbe...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04328961 · results posted 16 December 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT04328961) enrolled 829 adults in total — 422 in a group that received ascorbic acid (vitamin C) and 407 in a group that received hydroxychloroquine. The trial was looking at whether hydroxychloroquine could prevent COVID-19 infection in people who had recently been exposed to the virus (known as post-exposure prevention). Vitamin C was used as the comparison group. Participants collected their own swab samples daily for 14 days, and the main thing being measured was how many people in each group tested positive for the SAR...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, a very large amount of public research funding has been directed toward Long COVID in the United States. However, the direction of that funding is falling year on year, which may signal a shift in institutional priorities. For patients, this pattern is worth watching, as the overall level of investment has been substantial, but a continuing decline could affect how m...
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.